{"id":"ald403-eptinezumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Antibody formation"}]},"_chembl":{"chemblId":"CHEMBL3833320","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By neutralizing circulating CGRP, eptinezumab prevents its interaction with CGRP receptors on sensory neurons and blood vessels, thereby reducing migraine frequency and severity. This mechanism is distinct from traditional migraine treatments and represents a targeted approach to migraine prevention.","oneSentence":"Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:36.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Episodic migraine prevention"},{"name":"Chronic migraine prevention"}]},"trialDetails":[{"nctId":"NCT05635604","phase":"NA","title":"Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-03-01","conditions":"Migraine","enrollment":38},{"nctId":"NCT02974153","phase":"PHASE3","title":"Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2016-11","conditions":"Migraine Disorders","enrollment":1121},{"nctId":"NCT02559895","phase":"PHASE3","title":"A Multicenter Assessment of ALD403 in Frequent Episodic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2015-09","conditions":"Migraine Disorders","enrollment":898},{"nctId":"NCT02985398","phase":"PHASE3","title":"An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2016-12","conditions":"Migraine Disorder","enrollment":128},{"nctId":"NCT02275117","phase":"PHASE2","title":"A Multicenter Assessment of ALD403 in Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2014-10","conditions":"Migraine Disorders","enrollment":665},{"nctId":"NCT01772524","phase":"PHASE1","title":"Safety, Efficacy and Pharmacokinetics of ALD403","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2013-01","conditions":"Migraine","enrollment":163},{"nctId":"NCT01579383","phase":"PHASE1","title":"Safety Tolerability and Pharmacokinetics of ALD403","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2012-04","conditions":"Migraine Disorders","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":283,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eptinezumab-jjmr","Vyepti"],"phase":"phase_3","status":"active","brandName":"ALD403 (Eptinezumab)","genericName":"ALD403 (Eptinezumab)","companyName":"Alder Biopharmaceuticals, Inc.","companyId":"alder-biopharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Eptinezumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Episodic migraine prevention, Chronic migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}